Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ryan S. Burgos"'
Autor:
H. Josh Jang, Galen Hostetter, Alexander W. Macfarlane, Zachary Madaj, Eric A. Ross, Toshinori Hinoue, Justin R. Kulchycki, Ryan S. Burgos, Mahvish Tafseer, R. Katherine Alpaugh, Candice L. Schwebel, Rutika Kokate, Daniel M. Geynisman, Matthew R. Zibelman, Pooja Ghatalia, Peter W. Nichols, Woonbok Chung, Jozef Madzo, Noah M. Hahn, David I. Quinn, Jean-Pierre J. Issa, Michael J. Topper, Stephen B. Baylin, Hui Shen, Kerry S. Campbell, Peter A. Jones, Elizabeth R. Plimack
Publikováno v:
Clinical Cancer Research. 29:2052-2065
Purpose: On the basis of preclinical evidence of epigenetic contribution to sensitivity and resistance to immune checkpoint inhibitors (ICI), we hypothesized that guadecitabine (hypomethylating agent) and atezolizumab [anti–programmed cell death li
Autor:
Elizabeth R. Plimack, Peter A. Jones, Kerry S. Campbell, Hui Shen, Stephen B. Baylin, Michael J. Topper, Jean-Pierre J. Issa, David I. Quinn, Noah M. Hahn, Jozef Madzo, Woonbok Chung, Peter W. Nichols, Pooja Ghatalia, Matthew R. Zibelman, Daniel M. Geynisman, Rutika Kokate, Candice L. Schwebel, R. Katherine Alpaugh, Mahvish Tafseer, Ryan S. Burgos, Justin R. Kulchycki, Toshinori Hinoue, Eric A. Ross, Zachary Madaj, Alexander W. Macfarlane, Galen Hostetter, H. Josh Jang
Supplementary Figure 8: PD-L1 levels in tumor or tumor microenvironment does not associate with tumor progression or control.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e7a8eb8aff8605de7e80f259eb3a7f2
https://doi.org/10.1158/1078-0432.22587042
https://doi.org/10.1158/1078-0432.22587042
Autor:
Elizabeth R. Plimack, Peter A. Jones, Kerry S. Campbell, Hui Shen, Stephen B. Baylin, Michael J. Topper, Jean-Pierre J. Issa, David I. Quinn, Noah M. Hahn, Jozef Madzo, Woonbok Chung, Peter W. Nichols, Pooja Ghatalia, Matthew R. Zibelman, Daniel M. Geynisman, Rutika Kokate, Candice L. Schwebel, R. Katherine Alpaugh, Mahvish Tafseer, Ryan S. Burgos, Justin R. Kulchycki, Toshinori Hinoue, Eric A. Ross, Zachary Madaj, Alexander W. Macfarlane, Galen Hostetter, H. Josh Jang
Supplementary TablesSupplementary Table 1: Patient and tumor sample informationSupplementary Table 2: Tumor mutation burdenSupplementary Table 3: Unfiltered whole exome sequencing mutation analysisSupplementary Table 4: Filtered whole exome sequencin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::060df0332a16728b73018ccfae5db307
https://doi.org/10.1158/1078-0432.22587036.v1
https://doi.org/10.1158/1078-0432.22587036.v1
Autor:
Elizabeth R. Plimack, Peter A. Jones, Kerry S. Campbell, Hui Shen, Stephen B. Baylin, Michael J. Topper, Jean-Pierre J. Issa, David I. Quinn, Noah M. Hahn, Jozef Madzo, Woonbok Chung, Peter W. Nichols, Pooja Ghatalia, Matthew R. Zibelman, Daniel M. Geynisman, Rutika Kokate, Candice L. Schwebel, R. Katherine Alpaugh, Mahvish Tafseer, Ryan S. Burgos, Justin R. Kulchycki, Toshinori Hinoue, Eric A. Ross, Zachary Madaj, Alexander W. Macfarlane, Galen Hostetter, H. Josh Jang
Purpose:On the basis of preclinical evidence of epigenetic contribution to sensitivity and resistance to immune checkpoint inhibitors (ICI), we hypothesized that guadecitabine (hypomethylating agent) and atezolizumab [anti–programmed cell death lig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b15863b501539cdcb1e336129965c9e6
https://doi.org/10.1158/1078-0432.c.6571947.v1
https://doi.org/10.1158/1078-0432.c.6571947.v1
Publikováno v:
Immunotherapy Weekly; 4/4/2023, p1013-1013, 1p